Kaserta Therapeutics develops scalable, affordable bacteriophage‑based therapeutics to combat antimicrobial‑resistant infections, initially targeting high‑burden diseases in Africa. By leveraging virus‑driven bacterial targeting and AI‑enhanced data platforms, they create rapid, side‑effect‑reduced treatments that can adapt to evolving regulatory and market needs, aiming to deliver effective care for neglected infections worldwide.
Funding
Funding not disclosed
Founders
Product
Problem
Antimicrobial resistance is rapidly increasing in Africa, where high infectious disease burdens, limited diagnostic capacity, and reliance on ineffective antibiotics lead to frequent treatment failures. Existing drug development pipelines focus on high‑income markets and often do not address the specific pathogen profiles prevalent on the continent.
Solution
Kaserta Therapeutics builds bacteriophage‑based therapeutics that target resistant bacterial strains with high specificity. The platform integrates phage biology with AI‑driven data analysis to identify, engineer, and produce viral candidates quickly and at scale. By selecting phages that match local pathogen ecology, the approach reduces off‑target effects and shortens treatment courses. The company designs its manufacturing process for low cost, enabling affordable distribution in resource‑limited settings. Regulatory‑flexible development pipelines allow rapid adaptation to evolving guidelines, supporting broader global deployment after initial launch in Africa.
Target Audience
Primary customers are public health agencies, hospital networks, and NGOs in Africa seeking affordable treatments for multidrug‑resistant infections, as well as global pharmaceutical partners interested in licensing phage therapeutics for broader markets.
Features
- AI‑enabled screening of environmental phage libraries to match regional bacterial isolates
- Modular phage engineering workflow that accelerates candidate optimization and scale‑up
- GMP‑compatible production platform optimized for low‑cost manufacturing at high volumes
- Formulation strategies that enhance stability and delivery for oral or injectable use
- Data‑driven safety profiling to minimize side effects and ensure targeted bacterial killing